Kurt Graves, new i2o Therapeutics CEO

i2o Ther­a­peu­tics clos­es $46M Se­ries A, names Kurt Graves as CEO and ac­quires Intar­cia’s twice-re­ject­ed di­a­betes as­set

In a slew of com­pa­ny up­dates, i2o Ther­a­peu­tics has closed a Se­ries A raise worth $46 mil­lion from biotech in­vestors and named Kurt Graves as its new chair­man, pres­i­dent and CEO.

The biotech al­so ac­quired the car­diometa­bol­ic clin­i­cal pipeline of Intar­cia Ther­a­peu­tics, which has six can­di­dates, in­clud­ing IT­CA 650 — a type 2 di­a­betes drug/de­vice com­bo which has been re­ject­ed by the FDA twice. The oth­er five as­sets are all in the pre­clin­i­cal stage un­der con­sid­er­a­tion for T2D, non­al­co­holic steato­hep­ati­tis and obe­si­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.